Beyond the Prescription Pad: Improving Access to Advanced IBD Therapies

Release Date: December 20, 2018
Expiration Date: December 20, 2019

 

   Begin Activity        Resource Center        References & Glossary        Take Posttest

 

PROGRAM OVERVIEW

Despite marked advances in the understanding of the pathophysiology of inflammatory bowel disease (IBD) and the corresponding introduction of targeted treatment modalities with the potential to alter the natural history of the disease, clinical and endoscopic remission remain elusive goals for many patients. Several factors contribute to suboptimal outcomes in the treatment of patients with IBD, including an entrenched treatment paradigm that frequently results in the prolonged use of ineffective medications, uncertainty about the safety and efficacy profiles of medications in the expanding IBD armamentarium, and challenges obtaining insurance reimbursement for targeted biologic therapies. This program is designed to address these issues by educating clinicians about overall management approaches that have been demonstrated to improve outcomes in patients with IBD, and by educating clinicians on how to make safe and efficacious choices among established and emerging therapies. In addition, this program will also provide healthcare providers with guidance on strategies to obtain preauthorization and prevent denials in the present insurance environment, thus helping patients secure access to necessary therapies.

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be better able to:

  • Assess the evidence base on top-down and stepwise approaches for the management of ulcerative colitis (UC)
  • Select appropriate treatment targets for patients receiving treatment for UC based on safety and efficacy profiles of established and emerging therapies
  • Identify effective strategies for facilitating reimbursement for biologic therapies used in the treatment of patients with UC
FACULTY

David Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology, and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago
Chicago, Illinois

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact the Postgraduate Institute for Medicine at www.pimed.com.

TARGET AUDIENCE

This activity is intended for IBD specialists, gastroenterologists, gastroenterology advanced practice providers and nurses, and other healthcare providers engaged in the care of patients with IBD.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

David Rubin, MD
Consulting Fees: AbbVie, Abgenomics, Allergan, Inc., Amgen, Celgene Corporation, Ferring Pharmaceuticals, Inc., Forward Pharma, Janssen, Merck & Co., Inc., Medtronic, Napo Pharmaceuticals, Pfizer, Salix Pharmaceuticals, Inc., Shire, Takeda Pharmaceuticals U.S.A., Inc., Target PharmaSolutions, Inc.
Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus Laboratories, Shire, Takeda Pharmaceuticals U.S.A., Inc., UCB Pharma
Board of Trustees: American College of Gastroenterology
Co-Founder: Cornerstones Health, Inc., GoDuRn, LLC

Planners and Managers

The PIM planners and managers have nothing to disclose. The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME credit for this activity. During the period December 20, 2018 through December 20, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation at the end of this activity. Upon registering and successfully completing the post-test with a score of 80% or better and the activity evaluation, your certificate will be made available immediately.

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity hosted by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PROVIDER STATEMENT

Provided by Postgraduate Institute for Medicine.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Continue to Pretest